Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Warts - Pipeline Review, H2 2016, provides an overview of the Genital Warts (Infectious Disease) pipeline landscape.

Genital warts (condyloma acuminata) are one of the most common types of sexually transmitted infections. Genital warts are caused by the human papillomavirus (HPV). Symptoms include small, flesh-colored or gray swellings in genital area, itching or discomfort in genital area, pain during intercourse and frequent urination. Treatment includes antiviral drugs and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Warts - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Genital Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Warts (Condylomata Acuminata) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 8, 1, 4 and 2 respectively for Genital Warts.

Genital Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Warts (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Genital Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Genital Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Genital Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Genital Warts (Infectious Disease)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Genital Warts (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Genital Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

• Table of Contents
  • List of Tables
  • List of Figures
• Introduction
  • Global Markets Direct Report Coverage
• Genital Warts (Condylomata Acuminata) Overview
• Therapeutics Development
  • Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview
• Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies
• Genital Warts (Condylomata Acuminata) - Pipeline Products Glance
  • Clinical Stage Products
  • Early Stage Products
• Genital Warts (Condylomata Acuminata) - Products under Development by Companies
• Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development
  • Agilvax, Inc.
  • Aviragen Therapeutics, Inc.
  • Biogenomics Limited
  • BioMAS Ltd.
  • Cutanea Life Sciences Inc
  • Foamix Pharmaceuticals Ltd.
  • G&E Herbal Biotechnology Co., Ltd.
  • Laboratories Ojer Pharma S.L.
  • LEO Pharma A/S
  • Novan, Inc.
  • Novartis AG
  • Tamir Biotechnology, Inc.
  • Zydus Cadila Healthcare Limited
• Genital Warts (Condylomata Acuminata) - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
• Drug Profiles
  • AX-03 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • BTA-074 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • CB-0602 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • human papillomavirus vaccine - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • imiquimod - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • imiquimod SR - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • ingenol mebutate - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • interferon alfa-2b - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • LFX-453 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • omiganan pentahydrochloride - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • PP-210 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • ranpirnase - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • SB-206 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • SRT-100 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
• Genital Warts (Condylomata Acuminata) - Dormant Projects
• Genital Warts (Condylomata Acuminata) - Discontinued Products
• Genital Warts (Condylomata Acuminata) - Product Development Milestones
  • Featured News & Press Releases
    • May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206
    • May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
• Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

• Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2016
• Number of Products under Development by Companies, H2 2016
• Comparative Analysis by Clinical Stage Development, H2 2016
• Comparative Analysis by Early Stage Development, H2 2016
• Products under Development by Companies, H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by Aviragen Therapeutics, Inc., H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by Cutanea Life Sciences Inc, H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by Laboratories Ojer Pharma S.L., H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by Novartis AG, H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H2 2016
• Genital Warts (Condylomata Acuminata) - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
• Assessment by Monotherapy Products, H2 2016
• Number of Products by Stage and Target, H2 2016
• Number of Products by Stage and Mechanism of Action, H2 2016
• Number of Products by Stage and Route of Administration, H2 2016
• Number of Products by Stage and Molecule Type, H2 2016
• Genital Warts (Condylomata Acuminata) - Dormant Projects, H2 2016
• Genital Warts (Condylomata Acuminata) - Discontinued Products, H2 2016

List of Figures

• Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2016
• Number of Products under Development by Companies, H2 2016
• Comparative Analysis by Clinical Stage Development, H2 2016
• Comparative Analysis by Early Stage Products, H2 2016
• Assessment by Monotherapy Products, H2 2016
• Number of Products by Top 10 Targets, H2 2016
• Number of Products by Stage and Top 10 Targets, H2 2016
• Number of Products by Top 10 Mechanism of Actions, H2 2016
• Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
• Number of Products by Routes of Administration, H2 2016
• Number of Products by Stage and Routes of Administration, H2 2016
• Number of Products by Molecule Types, H2 2016
• Number of Products by Stage and Molecule Types, H2 2016